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Background: To investigate vascular-related pathophysiological characteristics of two human lung cancers with
modifiable vascularisation using MRI and CT.
Methods: Tumour xenografts with modifiable vascularisation were established in 71 rats (approval by the Animal
Care Committee was obtained) by subcutaneous transplantation of two human non-small-cell lung cancer (NSCLC)
cells (A549, H1299) either alone or co-transplanted with vascular growth promoters. The vascularity of the tumours
was assessed noninvasively by MRI diffusion-weighted-imaging (DWI), T2-weighted, and time-of-flight (TOF)
sequences) as well as contrast-enhanced CT (CE-CT), using clinical scanners. As a reference standard, histological
examinations (CD-31, fluorescent beads) were done after explantation.
Results: Microvessel density (MVD) was higher in co-transplanted tumours (171 ± 19 number/mm2) than in non-co-
transplanted tumours (111 ± 11 number/mm2; p = 0.002). Co-transplanted tumours showed higher growth rates and
larger tumour vessels at TOF-MRI as well as larger necrotic areas at CE-CT. In co-transplanted tumours, DWI revealed
higher cellularity (lower minimal ADCdiff 166 ± 15 versus 346 ± 27 mm
2/s × 10−6; p < 0.001), highly necrotic areas
(higher maximal ADCdiff 1695 ± 65 versus 1320 ± 59 mm
2/s × 10−6; p < 0.001), and better-perfused tumour stroma
(higher ADCperf 723 ± 36 versus 636 ± 51 mm
2/s × 10−6; p = 0.005). Significant correlations were found using
qualitative and quantitative parameters: maximal ADCperf and MVD (r = 0.326); maximal ADCdiff and relative necrotic
volume on CE-CT (r = 0.551); minimal ADCdiff and MVD (r = −0.395).
Conclusions: Pathophysiological differences related to vascular supply in two human lung cancer cell lines with
modifiable vascularity are quantifiable with clinical imaging techniques. Imaging parameters of vascularisation
correlated with the results of histology. DWI was able to characterise both the extent of necrosis and the level of
perfusion.
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 Rat xenograft tumours with modifiable angiogenesis
can be investigated using clinical scanners
 DWI characterises necrosis, perfusion, and
vascularisation in tumours with variable
vascularisation
 Differentiated views on ADCdiff give hints for
histological traits of tumour vascularisation
 CE-CT and TOF-MRI visualise parameters reflecting
vascularisation
 DWI, CE-CT, TOF-MRI noninvasively deliver data
characterising specific parameters of tumour patho-
physiology related to vascularity
Background
Angiogenesis is of fundamental importance for growing
tumours [1] and only by switching to an angiogenic
phenotype, followed by the development of new vascular-
isation, solid tumours can overcome a critical size of 1–
2 mm3 [2, 3]. Because of their own blood supply, cancer
cells in solid tumours become independent from nutrition
by diffusion of oxygen and nutrients from their surround-
ings. This lays the foundation for both the growth of the
primary tumour and the spreading of tumour cells
through the body. Characterisation of the vascularity of
tissues in patients through imaging predicts response to
therapy and correlates with prognosis [4].
Magnetic resonance imaging (MRI) of tumour vascu-
larisation in vivo can be facilitated by time-of-flight
(TOF) techniques for imaging the supplying tumour ves-
sels and by diffusion-weighted imaging (DWI) [5] meas-
uring the degree of the motion of free water in the
imaging target [6–9] by calculating the apparent diffu-
sion coefficient (ADC). Higher ADCs indicate fewer or
less functional cell membranes frequently found in areas
of necrosis or lower cellularity [10, 11]. Larger b-values
in DWI acquisition generate a greater sensitivity for dif-
fusion while with lower b-values gross motions within
the target tissue, such as perfusion as well as extravascu-
lar and extracellular microcirculation, contribute in-
creasingly to the received signal [11–13].
Contrast-enhanced computed tomography (CE-CT)
delivers other parameters connected to vascularisation.
Contrast enhancement is influenced by both vascularisa-
tion and the extravascular space and can be easily quan-
tified [14]. However, results of dynamic CE-CT (DCE-
CT) show considerable variations due to theoretical and
technical limitations [15].
The reference standard for quantification of tumour
vascularisation is immunohistology with different anti-
bodies [16]. The use of intravenously administered fluor-
escent beads is another possibility to quantify
vascularisation and perfusion [17]. Correlation with thereference standard is desirable to compare the results of
different imaging modalities that investigate characteris-
tics of vascularity.
The aim of this study was to investigate human lung
cancer xenografts with different degrees of vascularity
(tumour-induced and amplified), using different clinic-
ally available imaging techniques and to correlate these
results with histology and immunohistology.Methods
To examine the influence of vascularisation on imaging
parameters, a vascularisation-modifiable xenograft tumour
model consisting of human cancer cell lines was used in
this study. By the co-administration of vascular endothe-
lial cells as vascular growth promoters, the vascularisation
in tumours of the same cell line was manipulated [18–20].
This allows both to investigate the influence of vascular
structures and vascular perfusion and to exclude influ-
ences of different cancer cell lines on imaging parameters.
In this way, the differences related to the size of cells or
nuclei, to the tumour stroma and microenvironment, to
gene expression, and other cell-line characteristics should
be minimised.Cells, animals, and tumour transplantation
The human non-small cell lung cancer (NSCLC) cell
lines A549 and H1299 were investigated and rat glom-
erular endothelial (RGE) cells were used to modify vas-
cularity in these tumours.
The approval by the local Animal Care Committee
was obtained in accordance with the institutional guide-
lines and the national animal welfare regulations. Four
to 6-week-old athymic nude rats receiving food and
water ad libitum were used. To enable tumour growth,
all rats received one uniform whole-body irradiation of
4 Gy [21, 22]. Short anaesthesia during irradiation and
CE-CT was performed by intraperitoneal injection of
ketamine and xylazine [23], long anaesthesia during MRI
was done with gas narcosis using desflurane. Tumour
cells were transplanted 48 h after irradiation by subcuta-
neous injection of 200 μl of tumour cell suspension into
the right lower limb at the femur. The rats in the animal
experimental prospective cohort study were assigned
randomly to one of four groups (Fig. 1) and correspond-
ingly received 5 × 106 tumour cells, 2 × 106 RGE cells,
160 ng recombinant human vascular endothelial growth
factor 165 (rHu-VEGF-165), and 320 ng recombinant
human fibroblast growth factor b (rHu-FGF-b). After in-
jection, animals were inspected every 2 days and the tu-
mour’s length and width were measured by a caliper. As
soon as any tumour had reached a size of 20 mm in one
dimension, this tumour-bearing rat was subjected to the
multimodal imaging protocol.
Fig. 1 Stratification of four experimental groups with subcutaneously injected tumour cell suspensions and co-transplanted vascular growth promoters
(tumour cell lines: H1299 and A549). RGE, rat glomerular endothelial cells; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor
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The imaging of tumours included MRI, DWI, CE-CT,
and histological examinations. For CE-CT a positron
emission tomography (PET)/CT Biograph 16 (Siemens
AG, Erlangen, Germany) was used. A catheter implanted
into the jugular vein was used for intravenous applica-
tion of contrast material (Ultravist 370, Bayer Vital
GmbH, Leverkusen, Germany) and beads. The CT
protocol was: unenhanced CT scan; CE-CT after intra-
venous injection of 1 ml of contrast material using a
small-animal injection pump (Medtron, Saarbrücken,
Germany). The CT scan started 20 s after injection start.
The scan specifications were 80 kV and 100 mAs;
5122 pixels with a voxel resolution of 420 μm× 420 μm×
750 μm.
For MRI, a 1.5-T system and an eight-channel clinical
knee coil (Magnetom Avanto, Siemens AG, Erlangen)
were used. Rats were placed on a custom-made bed for
gas narcosis. The following sequences were performed:
T2-weighted turbo spin-echo (voxel size 0.6 mm3, time
of repetition [TR] 20.12 ms, time of echo [TE] 6.04 ms,
acquisition time 10 min and 53 s); three-dimensional
TOF (voxel size 0.3 mm3, TR 40 ms, TE 8.01 ms, acqui-
sition time 21 min and 46 s); DWI (voxel size 1.8 mm3,
TR 6300 ms, TE 94 ms, three orthogonal diffusion gradi-
ent directions, b-values 0, 50, 100, 150, 200, 250, 300,
500, 750, and 1000 s/mm2, acquisition time 17 min and
45 s).
Histology and immunohistology
Two hundred microlitres of suspension containing 2.4 ×
107 fluorescent beads (diameter 2.5 μm, excitation wave
length 633 nm; G. Kisker GbR, Steinfurt, Germany) were
injected via the jugular vein. After imaging and after
two min of beads’ circulation the rats were sacrificed and
the organs as well as the tumours were removed [17].
Representative slices (slice thickness 10 μm) of the
liver and kidneys (to verify appropriate application of
beads) as well as the tumours were stained with
hematoxylin-eosin. Tumour slices were additionally
stained with CD-31 antibody to quantify microvesseldensity (MVD). The quantification of beads embolised
into the vascularity of tumours was examined by fluores-
cent microscopy.
Image analysis
Histology and bead counts (beads: number of beads/field
of view) served as standard of reference and were ana-
lysed within the tumours, the liver, and the kidneys. For
CD-31 staining, tumour slices were digitally recorded at
20-fold magnification and the number of CD-31 posi-
tively stained structures were evaluated as published be-
fore, with MVD measured as the number of stained
structures/mm2 [16].
For analysis of CE-CT data, a contour was drawn
around the contrast-enhanced tumour in all slices, in-
cluding the outer rim of the tumour, the skin, and unen-
hanced lacunas but excluding bone and vessels without
contact to the tumour. Limits of density values for ana-
lysis of the entire tumour were -50 ≤HU ≤ +350. These
contours were copied to the plain CT series and mean
HU values in the tumours before and after contrast in-
jection were measured.
The MRI protocol contained morphological and func-
tional techniques. T2-weighted imaging served for co-
localisation and tumour volumetry, the latter was
obtained by manual segmentation. For visualisation of
vessels, TOF-angiography was done and an ordinal scale
was applied to the resulting three-dimensional image.
The comparison to the three-dimensional datasets of the
opposite femoral region was quantified according to the
following ordinal scale: tumours received zero points if
no differences in the visualisation of the vessels were de-
tectable, one point if an increased vascularisation was
visible, e.g. by separate short vessels, and two points if
large circumscribable vessels travelled through the
tumour. We did not use contrast-enhanced angiography
studies (neither CT angiography nor MR angiography)
for qualitative vessel visualisation since contrast bolus
timing for appropriate imaging is dependent on circulation
parameters that vary to a very high degree in sedated rats.
To evaluate the quantity of small vessels and related motion
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were utilised to separate apparent diffusion coefficients
(ADCs) [11] for diffusion (ADCdiff ) and perfusion
(ADCperf) [24]. Basically, for each slice, the images with b-
values of 500, 750, and 1000 s/mm2 were aggregated to cal-
culate eight-bit coloured ADCdiff maps and images with b-
values of 50, 100, and 150 s/mm2 were aggregated and sub-
tracted from ADCdiff maps to calculate eight-bit coloured
ADCperf maps. These were registered to the T2-weighted
image stacks and the contours of the tumours were copied
to the ADC maps to extract the minimum, maximum,
and mean ADCdiff and ADCperf.Statistical analysis
All statistical analyses were carried out with PASW 18
(Predictive Analytics SoftWare, IBM, Armonk, NY, USA)
by comparisons between co-transplanted and non-co-
transplanted tumours separated for each cell line as well
as averaged for both cell lines. The Kolmogorov-Smirnov
test was used to test for normality. The Mann–Whitney U
test was used to analyse non-normally distributed data,
whereas the t test was used for normally distributed data.
Spearman’s rank correlation coefficients were calculated
to evaluate correlations. The χ2 test was used to compare
the results of TOF sequences between the groups. A
p value lower than 0.050 was considered to indicate a sta-
tistically significant difference.Fig. 2 Growth of xenograft tumour volumes of the non-small-cell lung can
rat glomerular endothelial (RGE) cells, recombinant human vascular endotheli
fibroblast growth factor b (rHu-FGF-b) showed higher-volume growth as comResults
Cells, animals, and tumour transplantation
Both tumour cell lines H1299 and A549 revealed signifi-
cantly faster growth of the tumours in the co-transplanted
group as compared to the non-co-transplanted group
(Fig. 2). Tumours in animals with co-transplantation
reached imaging size earlier (Table 1). While bead embol-
isation in reference organs was not different between the
groups, the vascularisation in tumours quantified by MVD
and count of beads embolised into the tumours showed
significant differences (Table 1). MVD and bead count
were higher in co-transplanted tumours. For both cell
lines, the central regions of the co-transplanted tumours
often showed clusters of necrotic regions as well as vessels
with larger diameters often closely connected to clouds of
CD-31-positive small vessels (Fig. 3). Both necrotic areas
and CD-31-positive vessels with a wide diameter were
only rarely found in the centre of non-co-transplanted
tumours (Fig. 3).CT imaging
On unenhanced CT scans, co-transplanted tumours re-
vealed a trend towards lower HU values (30.5 ± 0.5 HU,
mean ± standard deviation), while non-co-transplanted
had higher HU values (32 ± 1 HU). After intravenously
administered contrast injection (Fig. 4), co-transplanted
tumours showed a higher contrast uptake (120 ± 2.2cer (NSCLC) cell lines A549 and H1299. Tumours co-transplanted with
al growth factor 165 (rHu-VEGF-165) and 320 ng recombinant human
pared to non-co-transplanted tumours
Table 1 Growth and histology
H1299 A549 All tumours
Non-co-
transplanted
co-
transplanted
p value Non-co-
transplanted
co-
transplanted
p
value
Non-co-
transplanted
co-transplanted p value
In vivo growth
duration
[days] 49.0 (20) 18.0 (11) <0.001 45.0 (10) 23.5 (15) <0.001 45.0 (7) 22.0 (12) <0.001
In vitro beads [number/
FOV]
1.1 (0.28) 1.3 (0.17) 0.009 1.1 (0.22) 1.3 (0.23) 0.032 1.1 (0.25) 1.3 (0.22) 0.001
In vitro MVD [number/
mm2]
89.7 (65.49) 203.1 (185.49) 0.036 114.6 (81.98) 153.4 (112.75) 0.018 110.8 (63.30) 171.4 (120) 0.002
FOV field of vision, MVD microvessel density
Overview of in vivo growth velocity until the imaging size of 2 cm was reached and in vitro histology and immunohistology. First and second column show results
separately for both cell lines, in the third column data for both tumour cell lines were merged. Median (interquartile range)
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This difference was highly significant (p = 0.001).
MRI
T2-weighted and TOF sequences
Higher volumes in the co-transplanted tumours than in
non-co-transplanted tumours were found (Table 2). TOF
sequences allowed the visualisation of vessels in all
xenograft tumours and revealed larger vessels in co-
transplanted tumours (Table 2).
DWI, ADCdiff, and ADCperf values
All ADC parameters were acquired in the kidneys in all
groups for reference and no significant difference for any
ADC parameter was found (data not shown). DWI revealed
significantly lower minimal ADCdiff values and significantly
higher maximal ADCdiff values in co-transplanted tumoursFig. 3 Vessel marker CD-31-positive structures (brown) in tumour sections.
and H1299, respectively, the left and right columns depict images for non-co-
clusters of compact vital tumour cells enclose to vessels in both co-transplant
CD-31-positive structures (brown) in both non-co-transplanted tumoursas compared to non-co-transplanted tumours (Table 2,
Fig. 5a). At DWI perfusion analysis, significantly higher
mean and maximal ADCperf values were found (Table 2,
Fig. 5b) in co-transplanted as compared to non-co-
transplanted tumours. The mean ADCperf values in H1299
tumours were significantly larger in co-transplanted than in
non-co-transplanted tumours (p = 0.001) while in
A549 tumours this difference was not significant
(Table 2).
Correlation analyses
The following correlations were found to be significant
considering all tumours: the correlation between max-
imal ADCperf and MVD (p = 0.010; r = 0.326; Fig. 6), the
correlation between mean ADCperf and contrast en-
hancement in whole tumour in CE-CT (p = 0.009; r =
0.294; Fig. 7), the correlation between maximal ADCdiffWhile the upper and lower rows depict images from cell lines A549
transplanted and co-transplanted tumours, respectively. Right column:
ed tumours. Left column: much looser cell clusters enclose to smaller
Fig. 4 Details of xenograft tumours and relevant regions of interests as acquired by contrast-enhanced computed tomography (CE-CT).
While the upper and lower rows depict images from cell lines A549 and H1299, respectively, the left and right columns depict images
for non-co-transplanted versus co-transplanted tumours, respectively. Left column: CT images of tumours from the non-co-transplantation
groups show comparatively homogenous hypodense and adjacent solid areas with limited contrast enhancement after intravenously administered
contrast injection. Right column: CT images of tumours from the co-transplantation groups show central areas predominantly liquid/cystic and strong,
most likely vascular, enhancement radiating into the tumour mass
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0.001; r = 0.551; Fig. 8) and the correlation between min-
imal ADCdiff and MVD (p = 0.002; r = −0.395; Fig. 9). For
technical reasons, the computer-based calculation of the
necrotic volume at CE-CT resulted in a value of 100%
for one rat which is the outlying value in Fig. 8. Exclud-
ing this data point from the correlation analysis in-
creases the correlation between the maximal ADCdiff
and relative necrotic volume estimated in CE-CT to p <
0.001; r = 0.594 (Spearman’s rank).Table 2 Study results magnetic resonance imaging (MRI) data
H1299 A54
Non-co-
transplanted
Co-
transplanted
p value Non
tran
Tumour
volume T2
[cm3] 1.6 (2.4) 3.8 (4.8) 0.001 0.2 (
TOF Numeric scale 1.3 ± 0.1 1.7 ± 0.1 0.009 1.2 ±
Maximal ADCdiff [mm
2/s ×
10−6]
1473 (616) 1672 (597) 0.047 1206
Minimal ADCdiff [mm
2/s ×
10−6]
311 (385) 149 (77) <0.001 348
Maximal ADCperf [mm
2/s ×
10−6]
1712 (830) 2994 (305) <0.001 1612
Mean ADCperf [mm
2/s ×
10−6]
568 (149) 722 (106) 0.001 646
In vivo MRI quantitative results of T2 volumetry, time-of-flight (TOF) and apparent d
both cell lines, third column tumour cell lines merged together. Median (interquartiDiscussion
The aim of this study was to evaluate imaging parame-
ters quantifying vascularity in human cancer xenografts
with two levels of vascularisation. The amount of vascu-
larisation was determined ex vivo by a reference stand-
ard, i.e. specific histological and immunohistological
methods. To provide translational results, these tumours
were investigated in vivo with scanners used in clinical
patient care. Clinically applied imaging techniques were
utilised and optimised for small-animal imaging.9 All tumours
-co-
splanted
Co-
transplanted
p
value
Non-co-
transplanted
Co-transplanted p value
0.3) 4.4 (6.5) 0.000 0.2 (1.7) 4.0 (5.2) <0.001
0.1 1.4 ± 0.1 0.009 1.2 ± 0.1 1.5 ± 0.1 0.006
(396) 1714 (674) 0.005 1320 (441) 1695 (546) <0.001
(199) 173 (135) <0.001 346 (224) 166 (97) <0.001
(614) 2999 (657) <0.001 1616 (661) 2999 (476) <0.001
(262) 723 (184) 0.203 636 (208) 723 (144) 0.005
iffusion coefficient (ADC). First and second column show results separated for
le range); TOF: mean ± SD
Fig. 5 a. Details of xenograft tumours: T2-weighted images fused on corresponding colour-coded apparent diffusion coefficient (ADC) maps. Upper
row: tumours from cell line A549; lower row: tumours from cell line H1299. Left column: non-co-transplanted tumours; right column: co-transplanted
tumours. Left column: the image fusion of the ADCdiff maps of non-co-transplanted tumours reveals comparatively homogenous and intermediate
values of diffusion (green). Right column: the image fusion of the ADCdiff maps of co-transplanted tumours reveals the existence of extreme values of
diffusion (red = high; dark blue = low). Range of ADCdiff (mm
2/s × 10−6) in the tumour were: top line left, 312–1593; top line right, 31–1586; lower line
left, 55–1920; lower line right, 30–2584. b. Details of xenograft tumours: T2-weighted images fused on corresponding colour-coded ADC maps. Upper
row: tumours from cell line A549; lower row: tumours from cell line H1299. Left column: non-co-transplanted tumours; right column: co-transplanted
tumours. Left column: the image fusion of the ADCperf maps of non-co-transplanted tumours reveals only very few vessels that are large enough to be
visualised (green dot). Right column: the image fusion of the ADCperf maps of co-transplanted tumours reveals larger perfused vessels
(green linear structures). Range of ADCperf (mm
2/s × 10−6) in the tumour were: top line left, 3–3502; top line right, 1–3977; lower line left,
1–2733; lower line right, 2–3920
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quently used in preclinical xenograft research, typically
on mice. In this study the authors decided to use a rat
model. These animals can carry larger tumour sizes that
mandate induction of relevant vascularisation to over-
come restrictions of oxygen diffusion distance and add-
itionally will develop relevant amounts of necrosis.Fig. 6 Spearman’s rank correlation between microvessel density (MVD) andMoreover, these tumour sizes are appropriate for evalu-
ation with clinical scanners and imaging protocols. Two
different lung cancer cell lines were utilised and both of
them were investigated either with or without co-
injection of vascular growth promoters (i.e. vascular
growth factors and rat endothelial cells) creating two dif-
ferent levels of vascular development in the growingmaximal ADCperf; p = 0.010; r = 0.326
Fig. 7 Spearman’s rank correlation between contrast enhancement in whole tumour in contrast-enhanced computed tomography and mean
ADCperf; p = 0.009; r = 0.294
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xenograft tumours is developed by the host animal, rat
vascular growth factors were used to modify vascularity.
Better tumour vascularisation causes a better supply of
oxygen and nutrients which results in a faster growth
rate. Nevertheless, growth rates are also dependent on
the pathophysiological properties of the individual tumour
cell line. Accordingly, after tumour and vascularity-Fig. 8 Spearman’s rank correlation between relative necrotic volume on co
p < 0.001; r = 0.551dependent growth times tumours were evaluated and dif-
ferent levels of vascularity were quantifiable with clinical
scanners and techniques.
Co-transplantation resulted in faster tumour growth.
Since the amount of transplanted tumour cells was con-
stant, the faster growth rate can be explained by a better
supply of oxygen and nutrients as well as an improved
evacuation of lactate and end products of metabolismntrast-enhanced computed tomography and maximal ADCdiff;
Fig. 9 Spearman’s rank correlation between microvessel density (MVD) and minimal ADCdiff; p = 0.002; r = −0.395
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for fast tumour growth is the angiogenic switch that is
dependent on endothelial precursor cells [25]. Beside all
other influences, co-transplantation with vascular
growth factors and rat endothelial cells increased the
probability of a successful switch to an angiogenic
phenotype which led to better vascularisation in these
tumours. This was proven in our study by the increases
of MVD and the larger amount of embolised beads
within the tumours. Interestingly, the co-transplanted
tumours grew so fast that the development of central
necrosis was higher in this group even though the num-
ber of larger vessels was also higher. In fact, CE-CT
showed wide hypodense areas within a contrast-
enhancing tumour parenchyma at the tumour rim and
around larger central vessels in co-transplanted tumours.
Using TOF sequences, co-transplanted tumours revealed
the development of larger vessels in contrast to non-co-
transplanted tumours. In summary, better vascularisa-
tion boosts fast growth which at the same time can in-
crease necrosis by uncoupling regions from blood supply
due to fast growth. Conversely, this means that regions
of necrosis may be an indirect indicator of better
vascularisation.
Adding a functional MRI technique, like quantitative
DWI, with the calculation of ADC values, increases the
diagnostic information. ADCdiff describes various prop-
erties of tumours. Higher ADCdiff values indicate higher
diffusion; that is equating with fewer or less functional
cell membranes frequently found in areas of necrosis or
lower cellularity. As known from biology and neurology,
necrosis is a continuum extending from viability to cellto tissue death. Therefore, a differentiated view on the
ADCdiff is required since the latter allows for detecting
different levels of necrosis.
Furthermore, ADCdiff conveys indirect information
concerning the viable part of the tumours and the condi-
tion of the tumour microenvironment [26]. The peak
value of ADCdiff (high maximal ADCdiff ) reflects the de-
gree of necrosis, whereas the nadir of ADCdiff (low min-
imal ADCdiff ) informs about the condition and cellular
density of the viable tumour cells. Both permit direct
and indirect interpretations on the level of vascularisa-
tion, blood supply, and the rate of growth. The range of
the ADCdiff values provides an additional source of in-
formation for a differentiated interpretation of ADCdiff.
The maximal ADCdiff in a tumour may reflect the extent
of necrosis in certain regions. As mentioned before, bet-
ter vascularisation induces faster tumour growth that
may impede the balance between nutrient supply and
nutrient demand which may trigger regional critical
shortness in blood supply leading to increased necrosis
[27, 28]. In addition, fast cellular growth rate is paral-
leled by the unorganised development of pathological
vessels leading to critical shortage of oxygen in highly
vascularised tumours. Such shortage leads to necrosis in
relevant parts of larger tumours. The formation of re-
gions with severe necrosis in better-vascularised tu-
mours can be the consequence. Such necrosis is not
seen in smaller tumours [29] because these tumours
show a slower growth rate with more adequate vascular
development and do not develop critically supplied areas
[28]. The histological findings in this study supported
this fact and are in agreement with the current knowledge
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cularised, large tumours, wide-diameter vessels, which
lack further small branches, were found traversing
through necrotic regions. Thus, nutrition in these regions
was limited to diffusion from one large single vessel. In
this respect, better-vascularised tumours exhibited areas
with more necrosis. These areas were formerly viable
tumour regions that lost their oxygen supply and became
necrotic. This situation was found less often in slower-
growing tumours. To sum up, tumours with better vascu-
larisation exhibit both severe necrosis and well-
vascularised areas. Consequently, the existence of large
necrotic areas in a tumour can be an indirect indicator for
good vascularisation. The differentiated view on ADCdiff
could detect this indicator. More precisely, the maximal
ADCdiff (high maximal values in a tumour) suggests the
existence of areas of high necrosis which is more often
found in better-vascularised tumours. Hence, a higher
maximal ADCdiff suggests better-vascularised tumours.
The results of this study support this fact. DWI is capable
of detecting these differences and was already found to
correlate with MVD [30]. The ADCdiff is much higher in
better-vascularised tumours because of the existence of
highly necrotic areas exhibiting high diffusion values [31].
The peak value of ADCdiff (maximal ADCdiff) indicates
focal areas of severe necrosis found in tumours with faster
growth due to better vascularisation. The latter was insuf-
ficient at some point of tumour growth resulting in critical
shortage of oxygen and nutrients and consecutive devel-
opment of necrosis. This may indicate a poorer prognosis
as Marconi et al. recently showed in women with
advanced-stage cervical cancer [32].
The interpretation of the minimal ADCdiff should
also be meaningful. The two major factors for im-
peded diffusion as estimated by the lowest values of
ADCdiff are the severely reduced intracellular space
(due to more organelles and larger nuclei) and extra-
cellular space (due to high proliferation rate) in viable
tumour tissue. In general, the lower ADCdiff values
correspond to higher cellularity and more compact
tumour tissue. Impeded diffusion in tumours occurs if
tumour cells can proliferate and form their typical
tumour microenvironment. However, such prolifera-
tion requires oxygen and nutrient supply and, there-
fore, the existence of a vascular system within the
tumour. As found herein, a low minimal ADCdiff may
indirectly indicate well-vascularised areas. The avail-
able academic literature gathered contradictory results
related to this topic. In women suffering from cervical
cancer, Nakamura et al. found that low ADC values
in the tumours were related to poor prognosis [33]
which supports the findings in this study, since
patients with highly vascularised tumours frequently
exhibit a poorer prognosis.In summary, the range of the ADCdiff is related to high
vascularisation. More precisely, higher maximal ADCdiff
values are associated with high necrosis as a conse-
quence of very fast tumour growth while very low min-
imal ADCdiff values are associated with high cellularity,
dense cell-cell contacts, and high protein expression as a
consequence of good proliferation. Both fast growth and
good proliferation may be surrogate parameters related
to better vascularisation.
The ADCperf is capable of detecting perfusion in tis-
sues directly and is related to vascularisation in tumours.
In this tumour model, highly vascularised and well-
perfused tumours exhibited higher ADCperf values, indi-
cating increased tumour vascularisation. This was shown
in both cell lines and was independent from the influence
of the histological cell type. The results of this study show
that the separation of the ADCs can provide physicians
with more information. However, in addition to the
suggestion by Koh et al. [12] that separating different
b-values may contribute to this, it was shown herein that
the differentiated analysis of minimal and maximal ADC
values may increase the value of the imaging [34, 35].
DWI can be used in extension to histology and other
imaging modalities. The evaluation of vascularisation in
tumours can be improved if different methods are used
in combination. ADCdiff, ADCperf, MVD, and other
methods detect correlated characteristics of vascularisa-
tion in tumours. The low, but significant, correlation be-
tween MVD and maximal ADCperf supports the idea
that both parameters are influenced by vascularisation
properties. The reason for the comparatively weak cor-
relation might be that both parameters are influenced by
different aspects of vascularisation. MVD is predomin-
antly influenced by the existence of vessels (which do
not necessarily have to be well perfused), whereas the
ADCperf is mainly influenced by the level of perfusion
(which is not necessarily linked to the existence of intact
vessel walls).
The correlation with the minimal ADCdiff values is
also in line with this concept. Well-vascularised tumours
developed areas with high proliferation and high cellu-
larity which may account for the correlation of MVD
and the minimal ADCdiff. This indicates that perfusion
and vascularisation in tumours affect the DWI values
obtained which was confirmed by the histological results
of this study. Much more than the ADCperf, the minimal
ADCdiff and the MVD are influenced by further aspects
of vascularisation. The authors speculate that the min-
imal ADCdiff is linked indirectly to vascularisation,
whereas MVD is connected much more closely to vascu-
larisation. While this might explain the small magnitude
of this correlation, a small, but significant, correlation
can be also meaningful. As described before, highly vas-
cularised fast-growing tumours reveal both well-perfused
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DWI implies that both methods capture this situation.
Necrotic areas were detected by high maximal ADCdiff
values. CE-CT visualised larger, comparatively necrotic,
volumes and stronger contrast enhancement in vascu-
larised areas. In this case, both parameters – the max-
imal ADCdiff and the relative necrotic volume in CE-CT
– are directly influenced by the same factor: the level of
necrosis. Both diffusion and contrast enhancement in-
crease with increasing levels of necrosis. Accordingly, a
moderately significant correlation was found. Thus,
DWI and CE-CT complement each other and extend the
insights in the tumour biology concerning vascularisation.
One limitation of this study is the utilisation of clinical
scanners for small-animal imaging with reduced reso-
lution as compared to dedicated preclinical scanners. To
overcome this disadvantage, a rat animal model was
used that allows the use of higher tumour volumes. The
frequently used mice tumour models only permit
smaller tumour sizes for animal welfare reasons. Tu-
mours of this size are difficult to scan with clinical scan-
ners [5]. In contrast, the rat tumours in this study were
at least two centimetres in maximal extension. The
pathophysiology related to vascularisation of tumours of
this size may be much more comparable to tumours in
patients since diffusion distances for oxygen and other
nutrients cannot cover comparatively large tumour vol-
umes, especially at the tumour margins. Tumour sizes
investigated in this study are dependent on sufficient
neovascularisation – as the tumours in patients are –
and should provide information more comparable to the
clinical situation. In diagnostic imaging of tumours of
patients, the presence of large necrotic areas (hypodense
in CE-CT in the venous phase) and highly vascularised
peripheral areas (hyperdense in CE-CT in the arterial
phase) is a frequent clinical finding. The applicability of
clinical imaging in this model is demonstrated by the
comparison to the histological and immunohistological
results. Furthermore, even though we pushed the im-
aging protocols to their limits, we believe that the results
found herein are a good basis for translating this to clin-
ical patient care.
With respect to DWI applications in oncology, the reli-
able transferability of ADC values between different im-
aging systems has been under discussion for many years
[36]. The definition of standardised technical protocols for
DWI and standardised interpretation of results are still
under evaluation and increasing consensus is developing
[37]. In our study, we used standardised parameters that
are applicable for clinical imaging and allow comparability
to other imaging systems. Using the comparison with hist-
ology, this research added new information to the current
research on how reliable ADC values for both diffusion
and perfusion are. The use of two different cell lines eachwith two different stages of vascular development reduced
the influences on imaging due to different histological
traits of different cell lines like protein expression, size,
and membrane permeability of the tumour cells. Conse-
quently, differences in imaging parameters within the
same tumour cell line are more likely caused by vascular-
isation rather than by characteristics of the cell line. This
is an important advantage compared to other research in-
vestigating histologically diverse tumour lines. The investi-
gated lung cancer cell lines are standard in preclinical
research and are previously well described. Further clinical
investigations will be developed taking advantage of the
results found herein.
The present study established a human tumour xeno-
graft cancer model with modifiable vascularisation and
successfully evaluated parameters reflecting vascularisa-
tion in tumours by noninvasive clinical imaging. Results
were correlated with histology and immunohistology.
The amount of necrosis and the pathologic tumour vas-
culature in tumours were visualised using clinical scan-
ners and were correlated with histological results. The
results of the study showed that DWI is capable of asses-
sing information not only on cell density but also indir-
ectly on the vascularisation in tumours. The differentiated
observation of DWI parameters increased the information
obtainable from imaging and provide additional parame-
ters that can be introduced to large-data analysis. ADCdiff
should be interpreted in its minimal, mean and maximal
extension. The harness of established clinical methods
(DWI, CE-CT, TOF) may by expanded by a better under-
standing of these imaging parameters. The results of this
study could contribute to this. This may give more infor-
mation concerning the aggressiveness of tumours, which
may influence therapy [4, 32, 33]. Additionally, this study
showed that clinical imaging units may well be used for
preclinical imaging, which allows faster translation of
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